New chemotherapy strategies for gastric cancer

In Vivo

Volumn 22, Issue 3, 2008, Pages 273-278

  Kubota, Tetsuro ^a  

^a KEIO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Adjuvant therapy; Advanced and recurrent; Gastric cancer; New drugs; Review

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; METHOTREXATE; S1;

ADJUVANT THERAPY; ANEMIA; ANOREXIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LYMPH NODE DISSECTION; MONOTHERAPY; NAUSEA; NEUTROPENIA; RECOMMENDED DRUG DOSE; REVIEW; STOMACH CANCER; STOMACH SURGERY; SURVIVAL TIME;

EID: 45949106605     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Sakata Y, Ohtsu A, Horikoshi N et al: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34(11): 1715-1720, 1998.
2. Koizumi W, Kurihara M, Nakano S et al: Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 58(3): 191-197, 2000.
3. Koizumi W, Tanabe S, Saigenji K et al: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 89(12): 2207-2212, 2003.
4. Shirasaka T, Nakano K, Takechi T et al: Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602-2606, 1996.
5. Boku N, Yamamoto S, Shirao K et al: Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J Clin Oncol 25(18S): 965s (abstract LBA4513), 2007.
6. Boku N, Ohtsu A, Shimada Y et al: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17(1): 319-323, 1999.
7. Koizumi W, Narahara H, Hara T et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology DOI:10.1016/ S1470-2045 (08)70035-4; http://www.thelancet.com/journals/lanonc/article/ PIIS1470204508700354/abstract?isEOP=true
8. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid= 441179&version=patient&protocolsearchid= 4216949#RegistryInfo_CDR0000441179
9. Imamura H, lishi H, Tsuburaya A et al: Irinotecan plus S-1 (IRI-S) versus S-1 alone as first line treatment for advanced gastric cancer: Results of a randomized phase III study (GC030/TOP-002). (Abstract #5, ASCO-GI 2008); http://www.asco.org/ASCO/ Abstracts+%26+Virtual+Meeting/Abstracts?&vmview= abst_detail_view&confID=53&abstractID=10303
10. Yoshida K, Ninomiya M, Takakura N et al: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12(11): 3402-3347, 2006.
11. Yamaguchi K, Shimamura T, Hyodo I et al: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12): 1803-1808, 2006.
12. http://clinicaltrials.gov/ct2/show/NCT00287768?term= JACCRO+GC-03&rank=1
13. Macdonald JS, Smalley SR, Benedetti J et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345(10): 725-730, 2001.
14. Cunningham D, Allum WH, Stenning SP et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11-20, 2006.
15. Sakuramoto S, Sasako M, Yamaguchi T et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18): 1810-1820, 2007.
16. Guideline for Treatment of Gastric Cancer (Japanese Gastric Cancer Association, 2nd edition), Tokyo, Kanehara Shuppan, p. 34, 2004.
17. Ohtsu A, Shimada Y, Shirao K et al: Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JC0G9205). J Clin Oncol 21(1): 54-59, 2003.
18. Van Cutsem E, Moiseyenko VM, Tjulandin S et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31): 4991-4997, 2006.